GlaxoSmithKline PakistanKAR:GLAXO +1.66%92 Gross Margin % is 37.49% as of Mar. 2026, which is 50% above its 10-year median of 24.95. GuruFocus rates KAR:GLAXO with a GF Score™ of 92/100 and a GF Value™ of ₨324.26 (Modestly Overvalued). The stock has 1 warning sign investors should review. Among 936 Drug Manufacturers companies, GlaxoSmithKline Pakistan ranks worse than 68.91% on this metric.
Warren Buffett believes that firms with excellent long term economics tend to have consistently higher margins.
Durable competitive advantage creates a high Gross Margin % because of the freedom to price in excess of cost. Companies can be categorized by their Gross Margin %
1. Greater than 40% = Durable competitive advantage
2. Less than 40% = Competition eroding margins
3. Less than 20% = no sustainable competitive advantage
Consistency of Gross Margin is key
GlaxoSmithKline Pakistan had a gross margin of 37.49% for the quarter that ended in Mar. 2026 => Competition eroding margins
Be Aware
If a company loses its competitive advantages, usually its gross margin declines well before its sales declines. Watching Gross Margin % and Operating Margin % closely helps avoid value trap situations.
GlaxoSmithKline Pakistan Gross Margin % Related Terms
GlaxoSmithKline Pakistan Gross Margin % Historical Data
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
KAR:GLAXO vs ZTS, UTHR, VTRS: Gross Margin % Comparison
For the Drug Manufacturers - Specialty & Generic subindustry, GlaxoSmithKline Pakistan's Gross Margin %, along with its competitors' market caps and Gross Margin % data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
GlaxoSmithKline Pakistan Gross Margin % vs Drug Manufacturers Industry
For the Drug Manufacturers industry and Healthcare sector, GlaxoSmithKline Pakistan's Gross Margin % distribution charts can be found below:
* The bar in red indicates where GlaxoSmithKline Pakistan's Gross Margin % falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
A positive Gross Profit is only the first step for a company to make a net profit. The gross profit needs to be big enough to also cover related labor, equipment, rental, marketing/advertising, research and development and a lot of other costs in selling the products.
GlaxoSmithKline Pakistan (KAR:GLAXO) has a Gross Margin % of 37.49% as of Mar. 2026. Gross margin is the ratio of total gross profit to net sales. View historical data on GlaxoSmithKline Pakistan and its competitors. This is 50% above median its historical median of 24.95. Over the past decade, GlaxoSmithKline Pakistan's Gross Margin % has ranged from 7.05 to 37.78. According to the industry distribution chart, GlaxoSmithKline Pakistan ranks #645 out of 936 companies in the Drug Manufacturers industry, placing it in the top 68.9%.
Is GlaxoSmithKline Pakistan's Gross Margin % too high?
GlaxoSmithKline Pakistan's current Gross Margin % of 37.49% is 50% above median its 10-year median of 24.95. Over the past 10 years, this metric has ranged from a low of 7.05 to a high of 37.78. The Drug Manufacturers industry median Gross Margin % is 48.50. GlaxoSmithKline Pakistan's value of 37.49% is 22.7% below this industry median. Based on the distribution chart, GlaxoSmithKline Pakistan ranks #645 out of 936 companies in the Drug Manufacturers industry, which is below the industry midpoint. Overall, GlaxoSmithKline Pakistan has a GF Score™ of 92/100 and is considered Modestly Overvalued, reflecting its overall financial health beyond just this single metric.
How does GlaxoSmithKline Pakistan's Gross Margin % compare to ZTS and UTHR?
According to the Drug Manufacturers industry distribution chart, GlaxoSmithKline Pakistan ranks #645 out of 936 companies for Gross Margin %. This places GlaxoSmithKline Pakistan in the lower half of its industry. The industry median Gross Margin % is 48.50. GlaxoSmithKline Pakistan's value of 37.49% is 22.7% below this benchmark. Historically, GlaxoSmithKline Pakistan's own Gross Margin % has ranged from 7.05 to 37.78 over the past decade. While the company's 10-year median is 24.95 vs. the industry median of 48.50, GlaxoSmithKline Pakistan has consistently been below the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Gross Margin % for a Drug Manufacturers company?
The median Gross Margin % among Drug Manufacturers companies is 48.50, based on 936 companies in the industry. Companies in the top quartile (top 25%) have a Gross Margin % significantly above this median, while those in the bottom quartile fall well below. However, Gross Margin % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. GlaxoSmithKline Pakistan's current Gross Margin % of 37.49% is 22.7% below the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Gross Margin % mean?
A high Gross Margin % can signal that a stock is expensive relative to its fundamentals. Gross margin is the ratio of total gross profit to net sales. View historical data on GlaxoSmithKline Pakistan and its competitors. For the Drug Manufacturers industry, the median Gross Margin % is 48.50 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. GlaxoSmithKline Pakistan's current Gross Margin % is 37.49%, which is 50% above median its own 10-year median of 24.95. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is GlaxoSmithKline Pakistan stock overvalued right now?
Based on GuruFocus' analysis, GlaxoSmithKline Pakistan (KAR:GLAXO) is currently considered Modestly Overvalued. The stock's GF Value™ is ₨324.26, compared to a current price of ₨370.25 — trading 14.2% above its estimated fair value. The current Gross Margin % is 37.49%, which is 50% above median its 10-year median of 24.95 and 22.7% below the Drug Manufacturers industry median of 48.50. GlaxoSmithKline Pakistan's overall GF Score™ is 92/100 with 1 warning sign to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Gross Margin % calculated?
Gross Margin % is calculated from a company's financial statements. For GlaxoSmithKline Pakistan (KAR:GLAXO), the current Gross Margin % is 37.49% as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is GlaxoSmithKline Pakistan (KAR:GLAXO) Overvalued in 2026?
Based on GuruFocus' analysis, GlaxoSmithKline Pakistan stock appears to be overvalued.
The current stock price of ₨370.25 is trading 14.2% above its estimated GF Value™ of ₨324.26.
GuruFocus considers GlaxoSmithKline Pakistan to be Modestly Overvalued.
Key valuation signals for KAR:GLAXO:
Gross Margin %: 37.49% (50% above median its 10-year median of 24.95)
GF Value™: ₨324.26 vs. price of ₨370.25 (14.2% above fair value)
Industry Position: 22.7% below the Drug Manufacturers median (#645 of 936)
No single metric tells the full story. See the KAR:GLAXO stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
GlaxoSmithKline Pakistan Ltd is engaged in the research, development, and manufacturing of pharmaceutical medicines, vaccines, and consumer healthcare products. It is involved in Anti-infective, Respiratory, Vaccines, Dermatological, Gastrointestinal, Analgesics, Urology, Central Nervous System, Allergy, Cardiovascular, and Vitamins therapy areas. The operating business divisions are Pharmaceuticals and Consumer Healthcare. The pharmaceutical brands of the company include Augmentin, Seretide, Amoxicillin, Velosef, Zantac, and Calpol, and prominent vaccines include Synflorix, Infanrix Hexa, Rotarix, Engerix-B, Havrix, and Cervarix. The company operates in single segment which is the Pharmaceuticals segment.
92GF Score
Get the complete analysis for KAR:GLAXO
Gross Margin % is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
KAR:GLAXO has been successfully added to your 
